Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMALIZUMAB Cause Clostridium difficile infection? 121 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 121 reports of Clostridium difficile infection have been filed in association with OMALIZUMAB (Omalizumab-igec). This represents 0.2% of all adverse event reports for OMALIZUMAB.

121
Reports of Clostridium difficile infection with OMALIZUMAB
0.2%
of all OMALIZUMAB reports
2
Deaths
80
Hospitalizations

How Dangerous Is Clostridium difficile infection From OMALIZUMAB?

Of the 121 reports, 2 (1.7%) resulted in death, 80 (66.1%) required hospitalization, and 1 (0.8%) were considered life-threatening.

Is Clostridium difficile infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMALIZUMAB. However, 121 reports have been filed with the FAERS database.

What Other Side Effects Does OMALIZUMAB Cause?

No adverse event (9,736) Asthma (9,354) Urticaria (9,231) Off label use (9,199) Dyspnoea (8,323) Drug ineffective (6,747) Cough (5,926) Pruritus (5,224) Fatigue (5,053) Malaise (4,820)

What Other Drugs Cause Clostridium difficile infection?

ADALIMUMAB (1,502) INFLIXIMAB (1,419) VEDOLIZUMAB (1,130) LENALIDOMIDE (814) VANCOMYCIN (743) METRONIDAZOLE (619) PREDNISONE (618) METHOTREXATE (588) RITUXIMAB (532) CIPROFLOXACIN (508)

Which OMALIZUMAB Alternatives Have Lower Clostridium difficile infection Risk?

OMALIZUMAB vs OMAVELOXOLONE OMALIZUMAB vs OMBITASVIR OMALIZUMAB vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMALIZUMAB vs OMEGA-3-ACID ETHYL ESTERS OMALIZUMAB vs OMEGA-3-CARBOXYLIC ACIDS

Related Pages

OMALIZUMAB Full Profile All Clostridium difficile infection Reports All Drugs Causing Clostridium difficile infection OMALIZUMAB Demographics